Latest Period
Q1 2026
Security Snapshot
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) Institutional Ownership
CUSIP: 78397T202
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
75
Shares (Excl. Options)
69,191,893
Price
$3.83
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- SABS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 69,191,893
- Total 13F value
- $265,013,025
- Portfolio coverage rank
- 0%
- Share change
- +31,992,821
- Value change
- +$122,542,646
- Number of holders
- 75
- Shares outstanding
- 76,568,369
- SEC-reported price per share
- $3.40
- Insider filing price
- $3.40
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 78397T202.
- 75 institutions reported positions in Q1 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 48 to 75 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $135,919,535 to $265,013,025.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 75 institutions filings for Q1 2026.
Security key
78397T202
Latest holder period
Q1 2026
13F holders
75
13D/G owners
10
CIK / CUSIP context first
Open Q1 2026 holders
SABS full holder history
SAB Biotherapeutics, Inc. SEC filings
SAB Biotherapeutics, Inc. company facts
SAB Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 78397T202:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
SABS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | $54,973,720 | 25,931,000 | Vivo Opportunity Fund Holdings, L.P. | 29 Sep 2025 | |||
| Caligan Partners LP | 10% | $31,072,107 | 7,967,207 | JOHNSON DAVID EDWARD | 31 Mar 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $30,195,359 | +$8,858,028 | 7,311,225 | +42% | RA Capital Management, L.P. | 19 Mar 2026 |
| Woodline Partners LP | 9.9% | $14,323,021 | 7,125,881 | Woodline Partners LP | 30 Sep 2025 | |||
| PERCEPTIVE ADVISORS LLC | 8.4% | +16% | $25,083,798 | +$11,543,540 | 6,431,743 | +85% | Perceptive Advisors LLC | 31 Mar 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | 10% | $19,850,762 | 5,089,939 | Balyasny Asset Management L.P. | 31 Mar 2026 | |||
| BIOTECHNOLOGY VALUE FUND L P | 9.1% | -8.9% | $18,761,910 | -$1,598,505 | 4,761,906 | -7.9% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Commodore Capital LP | 9.9% | $9,588,711 | 4,522,977 | Commodore Capital LP | 26 Sep 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 5.1% | $13,385,397 | 3,432,153 | Millennium Management LLC | 24 Apr 2026 | |||
| RTW INVESTMENTS, LP | 3.2% | -68% | $6,253,970 | +$2,218,090 | 1,587,302 | +55% | RTW Investments, LP | 31 Dec 2025 |
As of 31 Mar 2026, 75 institutional investors reported holding 69,191,893 shares of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS). This represents 90% of the company’s total 76,568,369 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
86%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 15% | 11,420,000 | 0% | 3.6% | $43,738,600 |
| Caligan Partners LP | 10% | 7,967,207 | 2.2% | $30,514,403 | |
| PERCEPTIVE ADVISORS LLC | 8.4% | 6,431,743 | +701% | 0.49% | $24,633,576 |
| Commodore Capital LP | 5.7% | 4,401,500 | 0% | 0.98% | $16,857,745 |
| RA CAPITAL MANAGEMENT, L.P. | 5.7% | 4,401,500 | 0% | 0.18% | $16,857,745 |
| Balyasny Asset Management L.P. | 4.9% | 3,760,439 | +691% | 0.03% | $14,402,481 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.4% | 3,405,553 | 0.02% | $13,043,268 | |
| MILLENNIUM MANAGEMENT LLC | 4% | 3,032,697 | +836% | 0.01% | $11,615,230 |
| Woodline Partners LP | 3.7% | 2,851,791 | +0.03% | 0.04% | $10,922,359 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 2,493,737 | 0% | 0% | $9,551,013 |
| Spruce Street Capital LP | 2.9% | 2,198,502 | 0% | 2% | $8,420,263 |
| Sessa Capital IM, L.P. | 2.9% | 2,198,457 | 0% | 0.16% | $8,420,090 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.9% | 1,481,660 | 0.13% | $5,674,758 | |
| AMERIPRISE FINANCIAL INC | 1.9% | 1,476,106 | +420% | 0% | $5,653,486 |
| Ensign Peak Advisors, Inc | 1.8% | 1,375,610 | 0.01% | $5,268,586 | |
| Soleus Capital Management, L.P. | 1.4% | 1,050,000 | 0.16% | $4,021,500 | |
| Propel Bio Management, LLC | 1.3% | 1,012,790 | +55% | 2.4% | $3,886,475 |
| Jefferies Financial Group Inc. | 1.2% | 903,094 | +56% | 0.04% | $3,458,850 |
| Blackstone Inc. | 1.1% | 860,170 | -60% | 0.01% | $3,294,451 |
| ExodusPoint Capital Management, LP | 1% | 768,627 | +793% | 0.03% | $2,943,841 |
| Affinity Asset Advisors, LLC | 0.75% | 575,000 | 0.13% | $2,202,250 | |
| Monashee Investment Management LLC | 0.65% | 500,000 | 1% | $1,915,000 | |
| MARSHALL WACE, LLP | 0.61% | 463,925 | +96% | 0% | $1,776,832 |
| DV Trading LLC | 0.52% | 400,000 | 0.14% | $1,532,000 | |
| AWM Investment Company, Inc. | 0.52% | 400,000 | +100% | 0.17% | $1,532,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 69,191,893 | $265,013,025 | +$122,542,646 | $3.83 | 75 |
| 2025 Q4 | 36,342,111 | $135,919,535 | +$25,718,819 | $3.74 | 48 |
| 2025 Q3 | 28,023,938 | $56,328,113 | +$52,469,483 | $2.01 | 34 |
| 2025 Q2 | 1,923,874 | $3,369,565 | -$378,633 | $1.76 | 25 |
| 2025 Q1 | 2,209,552 | $2,994,479 | -$1,776,863 | $1.36 | 26 |
| 2024 Q4 | 2,652,300 | $10,189,778 | -$1,266,185 | $3.79 | 26 |
| 2024 Q3 | 3,141,736 | $8,482,377 | +$68,507 | $2.70 | 24 |
| 2024 Q2 | 3,127,151 | $9,694,108 | -$923,501 | $3.10 | 21 |
| 2024 Q1 | 3,339,666 | $15,162,138 | -$15,603,353 | $4.54 | 23 |
| 2023 Q4 | 8,791,109 | $6,055,351 | +$6,055,351 | $0.69 | 3 |